Based on our data, applying JAK/stat3 inhibitors, either alone or in combination with anti‐PD‐L1 approach, may be an effective therapeutic approach to improve the efficacy of immunotherapy for prostate cancer. Here, STAT3 is linked to prostate carcinoma.